The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
This form is used to initiate the EFT registration process when the practice chooses not to use check reimbursements. It is a one-time registration completed by the practice.
This form is used when the drug is not clearly identified on the explanation of benefits (EOB). This form can accompany the EOB.
This form is used to initiate a one-time check reimbursement.
This form is used to initiate the check reimbursement process. It is a one-time registration completed by the practice.
OCREVUS is indicated for the treatment of:
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.
Most Common Adverse Reactions
RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions. PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.
The OCREVUS Prepaid MasterCard® is issued by Comerica Bank pursuant to license by MasterCard International. No cash or ATM access. The card can be used only to purchase prescriptions at participating merchant locations where Debit MasterCard is accepted.